Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
Duchenne Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy
About this trial
This is an interventional basic science trial for Duchenne Muscular Dystrophy
Eligibility Criteria
Inclusion Criteria: Genetically confirmed diagnosis of DMD or FSHD. Between 5 and 20 years of age for patients with DMD, or between 5 and 80 years of age for patients with FSHD. Ambulant (as defined by having the ability to walk without assistance for 10 meters) or non-ambulant DMD patients. Ambulant FSHD patients Non-ambulant DMD patients must be able to remain seated in an arm- or a wheel-chair for at least one hour. Signed informed consent form by patient himself or, in case of minor patients, signed informed consent form by patient's parents or legal guardians. Exclusion Criteria: Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed. Patients treated with corticosteroids for less than 6 months. Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs (for ambulant patients). A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion. Patients who are participating in an interventional clinical trial.
Sites / Locations
- CHR de la CitadelleRecruiting
Arms of the Study
Arm 1
Other
Patients with DMD/FSHD or control subjects
Patients and control subjects will be included over a one-year study period. Patients will be examined by a neuropaediatrician or neurologist and perform standardized assessments (timed tests, motor function tests, and strength tests) at baseline, 6 and 12 months. Patients will be asked to wear the device during one year. Control subjects will be examined by a physician and perform the same tests than those for ambulant patients at baseline and 12 months. Control subjects will be asked to wear the device for two months (one month at inclusion, one month 11 months after inclusion).